PRDM1 and autoimmune disease: Intriguingly, given the failure of Emab to demonstrate efficacy in a general SLE patient population, levels of Blimp1 expression could possibly be used as a biomarker to predict clinical responses to Emab in SLE and in patients with other autoimmune diseases.